Express Scripts (ESRX) 72.29 $ESRX
Liberty Medical Supply Highlights the Impact of the Alleged Inequitable Conduct of Express Scripts' Subsidiary, Medco Health Solutions, On Liberty's Chapter 11 Exit Strategy
PR Newswire - Thu Apr 17, 11:00AM CDT
Liberty Medical Supply, Inc., together with its parent company FGST Investments, Inc., holding company, ATLS Acquisition, LLC., and Polymedica Corporation, the legacy parent company of Liberty Healthcare Group, Inc., and their collective affiliates (collectively, "Liberty" or "the Company"
, today reaffirmed its commitment to supporting its patients, business partners, employees and communities as it takes the necessary steps to restructure under chapter 11 of the U.S. Bankruptcy Code. Liberty is focused on operating in the normal course of business while it develops its exit strategy from chapter 11 and positions itself for long-term success.
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Express Scripts Holding Company Announces First Quarter 2014 Earnings Conference Call
GlobeNewswire - Tue Apr 15, 2:00PM CDT
Express Scripts Holding Company (Nasdaq:ESRX), the largest pharmacy benefit management company in North America, announced today its intention to release its first quarter earnings on Tuesday, April 29, 2014 after the market closes and will hold its quarterly conference call to discuss first quarter results on Wednesday, April 30, 2014, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
Is This the Answer to Expensive Hepatitis-C Cures?
David Williamson, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
The fierce battle over the hepatitis C space continued to intensify today, as the market received a huge amount of clinical trial data news, from Gilead , Bristol-Myers Squibb , and now, Merck . Merck marks the newest entrant to the field with...
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam
Business Wire - Mon Apr 14, 1:24PM CDT
--At $1,000 a pill, industry sources say Sovaldi's price suggests a retail markup of 279,000% over production costs.
Express Scripts' Obamacare Data: What You Need to Know
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Apr 13, 6:00PM CDT
Investors interested in Obamacare certainly got a lot of news this past week. The Obama administration announced that Obamacare has enrolled 7.5 million Americans -- a milestone well above analyst and investor expectations just a couple weeks ago --...
Obamacare Enrollment: Quantity OK, Quality Questionable?
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 12:00PM CDT
Quantity versus quality? The age-old question appears to have raised its head again with the latest information about enrollment in the Affordable Care Act, commonly referred to as Obamacare. According to the White House, over 7.5 million Americans...
The Hepatitis C Cure Poised to "Break the Country"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Apr 12, 7:05AM CDT
Gilead 's Sovaldi is reportedly flying off the shelves, but bad press due to pushback from payers, members of Congress, and even the WHO continues to roll in. At issue is the high price of Sovaldi in the U.S. -- $84,000 for a full course of...
Campaign for Wider Reach, Clinical Trial Results, Recognitions, Earnings Release Schedule, and Favorable Ruling - Analyst Notes on Cigna, Medtronic, WellPoint, Mylan, and Express Scripts
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cigna Corp. (NYSE: CI), Medtronic, Inc. (NYSE: MDT), WellPoint Inc. (NYSE: WLP), Mylan, Inc. (NASDAQ: MYL), and Express Scripts Inc. (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Express Scripts Falls 3.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Apr 10, 3:57PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $71.66 to a high of $74.89. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $71.96 on volume of 8.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 3.06% Loss
Comtex SmarTrend(R) - Thu Apr 10, 3:57PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $71.66 to a high of $74.89. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $71.96 on volume of 8.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stunning Spending Growth Prediction for Hepatitis C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 10, 1:30PM CDT
Express Scripts 2013 Drug Trend Report included a jaw-dropping prediction that spending on hepatitis C treatment would surge by more than 100% this year and by more than 200% in both 2015 and 2016. For comparison, Express Scripts estimates...
Acquisitions, Trial Study Results, Drug Trend Reports, Conference Call Schedules, and Product Launches - Analyst Notes on Mallinckrodt, Amgen, Express Scripts, CR Bard, and Jazz
PR Newswire - Thu Apr 10, 10:36AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cost Increases Drive Higher Drug Trend for Workers' Compensation
PR Newswire - Thu Apr 10, 8:00AM CDT
Significant increases in cost per prescription drove drug trend for workers' compensation payers higher in 2013, according to research released this week by Express Scripts (NASDAQ: ESRX). Overall pharmacy spending for workers' compensation increased 9.5 percent, according to the Express Scripts Workers' Compensation Drug Trend Report, primarily from an 8.2 percent jump in cost per prescription. Effective management programs helped keep utilization increases to just over 1 percent.
Report: Exchanges yield more specialty drug claims
By TOM MURPHY - AP - Wed Apr 09, 1:11PM CDT
Patients from the health care overhaul's new insurance exchanges have been more likely to use expensive specialty drugs for chronic conditions, according to data from the nation's largest pharmacy benefits manager.
Express Scripts Analysis Reveals First Look at Medication Utilization Trends Among Public Health Insurance Exchange Enrollees
PR Newswire - Wed Apr 09, 7:00AM CDT
In a first look at pharmacy trends in Public Health Insurance Exchange plans, use of specialty medications was greater among Exchange enrollees versus patients enrolled in a commercial health plan, according to new research presented today by Express Scripts (NASDAQ: ESRX).
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Watch for Shares of Express Scripts (ESRX) to Approach Support at $71.71
Comtex SmarTrend(R) - Tue Apr 08, 10:16AM CDT
Shares of Express Scripts (NASDAQ:ESRX) opened today below their pivot of $72.86 and have already reached the first level of support at $72.21. Investors may be interested in a cross of the next downside pivot targets of $71.71 and $70.56.
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
Liberty Medical Supply Highlights the Impact of the Alleged Inequitable Conduct of Express Scripts' Subsidiary, Medco Health Solutions, On Liberty's Chapter 11 Exit Strategy
PR Newswire - Thu Apr 17, 11:00AM CDT
Liberty Medical Supply, Inc., together with its parent company FGST Investments, Inc., holding company, ATLS Acquisition, LLC., and Polymedica Corporation, the legacy parent company of Liberty Healthcare Group, Inc., and their collective affiliates (collectively, "Liberty" or "the Company"
, today reaffirmed its commitment to supporting its patients, business partners, employees and communities as it takes the necessary steps to restructure under chapter 11 of the U.S. Bankruptcy Code. Liberty is focused on operating in the normal course of business while it develops its exit strategy from chapter 11 and positions itself for long-term success. Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...
Express Scripts Holding Company Announces First Quarter 2014 Earnings Conference Call
GlobeNewswire - Tue Apr 15, 2:00PM CDT
Express Scripts Holding Company (Nasdaq:ESRX), the largest pharmacy benefit management company in North America, announced today its intention to release its first quarter earnings on Tuesday, April 29, 2014 after the market closes and will hold its quarterly conference call to discuss first quarter results on Wednesday, April 30, 2014, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).
Is This the Answer to Expensive Hepatitis-C Cures?
David Williamson, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
The fierce battle over the hepatitis C space continued to intensify today, as the market received a huge amount of clinical trial data news, from Gilead , Bristol-Myers Squibb , and now, Merck . Merck marks the newest entrant to the field with...
AHF: Anti-Gilead Drug Pricing Campaign Picks Up Steam
Business Wire - Mon Apr 14, 1:24PM CDT
--At $1,000 a pill, industry sources say Sovaldi's price suggests a retail markup of 279,000% over production costs.
Express Scripts' Obamacare Data: What You Need to Know
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Apr 13, 6:00PM CDT
Investors interested in Obamacare certainly got a lot of news this past week. The Obama administration announced that Obamacare has enrolled 7.5 million Americans -- a milestone well above analyst and investor expectations just a couple weeks ago --...
Obamacare Enrollment: Quantity OK, Quality Questionable?
Keith Speights, The Motley Fool - Motley Fool - Sun Apr 13, 12:00PM CDT
Quantity versus quality? The age-old question appears to have raised its head again with the latest information about enrollment in the Affordable Care Act, commonly referred to as Obamacare. According to the White House, over 7.5 million Americans...
The Hepatitis C Cure Poised to "Break the Country"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sat Apr 12, 7:05AM CDT
Gilead 's Sovaldi is reportedly flying off the shelves, but bad press due to pushback from payers, members of Congress, and even the WHO continues to roll in. At issue is the high price of Sovaldi in the U.S. -- $84,000 for a full course of...
Campaign for Wider Reach, Clinical Trial Results, Recognitions, Earnings Release Schedule, and Favorable Ruling - Analyst Notes on Cigna, Medtronic, WellPoint, Mylan, and Express Scripts
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cigna Corp. (NYSE: CI), Medtronic, Inc. (NYSE: MDT), WellPoint Inc. (NYSE: WLP), Mylan, Inc. (NASDAQ: MYL), and Express Scripts Inc. (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Express Scripts Falls 3.06% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Apr 10, 3:57PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $71.66 to a high of $74.89. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $71.96 on volume of 8.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Express Scripts After 3.06% Loss
Comtex SmarTrend(R) - Thu Apr 10, 3:57PM CDT
Express Scripts (NASDAQ:ESRX) traded in a range yesterday that spanned from a low of $71.66 to a high of $74.89. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $71.96 on volume of 8.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Stunning Spending Growth Prediction for Hepatitis C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 10, 1:30PM CDT
Express Scripts 2013 Drug Trend Report included a jaw-dropping prediction that spending on hepatitis C treatment would surge by more than 100% this year and by more than 200% in both 2015 and 2016. For comparison, Express Scripts estimates...
Acquisitions, Trial Study Results, Drug Trend Reports, Conference Call Schedules, and Product Launches - Analyst Notes on Mallinckrodt, Amgen, Express Scripts, CR Bard, and Jazz
PR Newswire - Thu Apr 10, 10:36AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX), CR Bard Inc. (NYSE: BCR), and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cost Increases Drive Higher Drug Trend for Workers' Compensation
PR Newswire - Thu Apr 10, 8:00AM CDT
Significant increases in cost per prescription drove drug trend for workers' compensation payers higher in 2013, according to research released this week by Express Scripts (NASDAQ: ESRX). Overall pharmacy spending for workers' compensation increased 9.5 percent, according to the Express Scripts Workers' Compensation Drug Trend Report, primarily from an 8.2 percent jump in cost per prescription. Effective management programs helped keep utilization increases to just over 1 percent.
Report: Exchanges yield more specialty drug claims
By TOM MURPHY - AP - Wed Apr 09, 1:11PM CDT
Patients from the health care overhaul's new insurance exchanges have been more likely to use expensive specialty drugs for chronic conditions, according to data from the nation's largest pharmacy benefits manager.
Express Scripts Analysis Reveals First Look at Medication Utilization Trends Among Public Health Insurance Exchange Enrollees
PR Newswire - Wed Apr 09, 7:00AM CDT
In a first look at pharmacy trends in Public Health Insurance Exchange plans, use of specialty medications was greater among Exchange enrollees versus patients enrolled in a commercial health plan, according to new research presented today by Express Scripts (NASDAQ: ESRX).
Nike Sprints Higher as the Dow Dips Again
Dan Carroll, The Motley Fool - Motley Fool - Tue Apr 08, 1:39PM CDT
While stocks have bounced back from yesterday's big losses as the markets approach earnings season again, one index is heading down again. As of 2:35 p.m. EDT, the Dow Jones Industrial Average was just under breakeven, with blue-chip member stocks...
Healthcare Investors Suffering Losses While Drug-Pricing War Rages
at The Street - Tue Apr 08, 10:23AM CDT
The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a...
Watch for Shares of Express Scripts (ESRX) to Approach Support at $71.71
Comtex SmarTrend(R) - Tue Apr 08, 10:16AM CDT
Shares of Express Scripts (NASDAQ:ESRX) opened today below their pivot of $72.86 and have already reached the first level of support at $72.21. Investors may be interested in a cross of the next downside pivot targets of $71.71 and $70.56.
Jim Cramer's Stop Trading: GILD ESRX
at The Street - Tue Apr 08, 9:59AM CDT
In the battle between Gilead and Express Scripts over the cost of hepatitis C pill Sovaldi, Gilead wins, Cramer asserts.
